A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

NCT05941897 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic NSCLC

Interventions

DRUG: Ceralasertib
DRUG: Durvalumab

Sponsor

AstraZeneca